Immix biopharma doses 1st patient in u.s. al amyloidosis trial with car-t nxc-201

Los angeles, july 08, 2024 (globe newswire) -- immix biopharma, inc. (“immixbio”, “company”, “we” or “us”, “immx”) (nasdaq: immx), a clinical-stage biopharmaceutical company trailblazing cell therapies in al amyloidosis and autoimmune disease, today announced that the 1st patient has been dosed at mskcc in its u.s. nexicart-2 trial with nxc-201, a sterically-optimized bcma-targeted car-t cell therapy.
CAR Ratings Summary
CAR Quant Ranking